|
|
Exchange: |
N/A |
Security
Type: |
Common |
Shares
Out: |
40,010,000 |
Market
Cap: |
482.92(M) |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$4.86 - $18.69 |
|
Level
I Sector: |
N/A |
Level
II Sector: |
N/A |
Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : 14.7 |
Insider 3/6 Months : 15.3 |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile Y-mAbs Therapeutics is a commercial-stage biopharmaceutical company focused on the development and commercialization of antibody based therapeutic products for the treatment of cancer. Co.'s approved drug DANYELZA® (naxitamab-gqgk) was approved by the U.S. Food and Drug Administration for the treatment, in combination with Granulocyte-Macrophage Colony-Stimulating Factor of pediatric patients one year of age and older and adult patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow who have demonstrated a partial response, minor response, or stable disease to prior therapy.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
268,008 |
558,056 |
762,731 |
Total Buy Value |
$0 |
$1,869,288 |
$3,530,830 |
$5,499,522 |
Total People Bought |
0 |
2 |
2 |
3 |
Total Buy Transactions |
0 |
8 |
14 |
17 |
Total Shares Sold |
99,644 |
249,644 |
399,644 |
399,644 |
Total Sell Value |
$1,238,854 |
$2,239,854 |
$3,035,237 |
$3,035,237 |
Total People Sold |
4 |
4 |
4 |
4 |
Total Sell Transactions |
7 |
10 |
12 |
12 |
End Date |
2024-03-05 |
2023-12-03 |
2023-06-04 |
2022-06-04 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Kruse Bo |
EVP, CFO, SECRY & TREAS. |
|
2024-05-31 |
4 |
S |
$12.07 |
$378,648 |
D/D |
(31,371) |
210,877 |
|
- |
|
Kruse Bo |
EVP, CFO, SECRY & TREAS. |
|
2024-05-31 |
4 |
OE |
$2.00 |
$62,742 |
D/D |
31,371 |
242,248 |
|
- |
|
Kruse Bo |
EVP, CFO, SECRY & TREAS. |
|
2024-05-30 |
4 |
S |
$12.03 |
$344,407 |
D/D |
(28,629) |
210,877 |
|
-1% |
|
Kruse Bo |
EVP, CFO, SECRY & TREAS. |
|
2024-05-30 |
4 |
OE |
$2.00 |
$57,258 |
D/D |
28,629 |
239,506 |
|
- |
|
Gad Thomas |
CHIEF BUSINESS OFFICER |
|
2024-05-23 |
4 |
S |
$13.00 |
$95,563 |
I/I |
(7,351) |
232,681 |
|
2% |
|
Gad Thomas |
CHIEF BUSINESS OFFICER |
|
2024-05-21 |
4 |
S |
$12.00 |
$300,000 |
I/I |
(25,000) |
240,032 |
|
4% |
|
Tagliaferri Mary |
Director |
|
2024-03-12 |
4 |
A |
$0.00 |
$0 |
D/D |
4,660 |
4,660 |
|
- |
|
Smith Susan Laura |
SVP & CHIEF COMMERCIAL OFFICER |
|
2024-03-05 |
4 |
S |
$16.55 |
$27,837 |
D/D |
(1,682) |
33,918 |
|
27% |
|
Gad Thomas |
CHIEF BUSINESS OFFICER |
|
2024-03-05 |
4 |
S |
$16.44 |
$64,116 |
D/D |
(3,900) |
158,700 |
|
27% |
|
Rajah Vignesh |
SVP & CHIEF MEDICAL OFFICER |
|
2024-03-05 |
4 |
S |
$16.53 |
$28,283 |
D/D |
(1,711) |
33,889 |
|
27% |
|
Rossi Michael J |
PRESIDENT & CEO |
|
2024-02-12 |
4 |
A |
$0.00 |
$0 |
D/D |
35,700 |
35,700 |
|
- |
|
Rajah Vignesh |
SVP & CHIEF MEDICAL OFFICER |
|
2024-01-18 |
4 |
A |
$0.00 |
$0 |
D/D |
17,800 |
35,600 |
|
- |
|
Kruse Bo |
EVP, CFO, SECRY & TREAS. |
|
2024-01-18 |
4 |
A |
$0.00 |
$0 |
D/D |
18,100 |
210,877 |
|
- |
|
Smith Susan Laura |
SVP & CHIEF COMMERCIAL OFFICER |
|
2024-01-18 |
4 |
A |
$0.00 |
$0 |
D/D |
17,800 |
35,600 |
|
- |
|
Wilms Joris |
SVP & CHIEF OPERATING OFFICER |
|
2024-01-18 |
4 |
A |
$0.00 |
$0 |
D/D |
17,800 |
35,600 |
|
- |
|
Lisby Steen |
SVP & CHIEF SCIENTIFIC OFFICER |
|
2024-01-18 |
4 |
A |
$0.00 |
$0 |
D/D |
17,800 |
35,600 |
|
- |
|
Lund-Hansen Torben |
SVP & CHIEF TECHNICAL OFFICER |
|
2024-01-18 |
4 |
A |
$0.00 |
$0 |
D/D |
17,800 |
35,600 |
|
- |
|
Gad Thomas |
CHIEF BUSINESS OFFICER |
|
2024-01-18 |
4 |
A |
$0.00 |
$0 |
D/D |
22,100 |
162,600 |
|
- |
|
Gad Thomas |
Chief Business Officer |
|
2023-12-21 |
4 |
OE |
$2.00 |
$100,000 |
D/D |
50,000 |
140,500 |
|
- |
|
Gad Thomas |
Chief Business Officer |
|
2023-12-15 |
4 |
S |
$6.61 |
$330,500 |
I/I |
(50,000) |
265,032 |
|
-134% |
|
Gad Thomas |
Chief Business Officer |
|
2023-12-14 |
4 |
S |
$6.83 |
$341,500 |
I/I |
(50,000) |
315,032 |
|
-113% |
|
Gad Thomas |
Chief Business Officer |
|
2023-12-13 |
4 |
S |
$6.58 |
$329,000 |
I/I |
(50,000) |
365,032 |
|
-117% |
|
Wedell-Wedellsborg Johan |
Director |
|
2023-12-11 |
4 |
B |
$6.85 |
$44,232 |
I/I |
6,455 |
4,559,233 |
2.1 |
130% |
|
Wg Biotech Aps |
Director |
|
2023-12-11 |
4 |
B |
$6.85 |
$44,232 |
D/D |
6,455 |
4,559,233 |
2.39 |
130% |
|
Wg Biotech Aps |
Director |
|
2023-12-11 |
4 |
B |
$7.01 |
$720,843 |
D/D |
102,863 |
4,552,778 |
2.39 |
130% |
|
255 Records found
|
|
Page 1 of 11 |
|
|